Page 30 - Read Online

Page 12 of 13 da Fonseca et al. Hepatoma Res 2019;5:37 I http://dx.doi.org/10.20517/2394-5079.2019.012

16. Shetty S, Lalor PF, Adams DH. Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity. Nat Rev Gastroenterol Hepatol
2018;15:555-67.
17. Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol 2013;3:785-97.
18. Fu J, Xu D, Liu Z, Shi M, Zhao P, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in
hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-39.
19. Sprinzl MF, Galle PR. Immune control in hepatocellular carcinoma development and progression: role of stromal cells. Semin Liver
Dis 2014;34:376-88.
20. Mollinedo F. Neutrophil degranulation, plasticity, and cancer metastasis. Trends Immunol 2019;40:228-42.
21. Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, et al. Tumor-associated neutrophils recruit macrophages and T-regulatory cells to
promote progression of hepatocellular carcinoma and resistance to Sorafenib. Gastroenterology 2016;150:1646-58.e17.
22. Draghiciu O, Lubbers J, Nijman HW, Daemen T. Myeloid derived suppressor cells-An overview of combat strategies to increase
immunotherapy efficacy. Oncoimmunology 2015;4:e954829.
23. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment.
Trends Immunol 2016;37:208-20.
24. Mizukoshi E, Yamashita T, Arai K, Terashima T, Kitahara M, et al. Myeloid-derived suppressor cells correlate with patient outcomes
in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Immunol Immunother 2016;65:715-25.
25. Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, et al. Programmed death ligand 1 expression in hepatocellular
carcinoma: Relationship With clinical and pathological features. Hepatology 2016;64:2038-46.
26. Yan W, Liu X, Ma H, Zhang H, Song X, et al. Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of
macrophages. Gut 2015;64:1593-604.
27. Budhu A, Forgues M, Ye QH, Jia HL, He P, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular
carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006;10:99-111.
28. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with
increased patient survival. Genome Res 2014;24:743-50.
29. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
30. Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, et al. Whole-genome mutational landscape and characterization of noncoding
and structural mutations in liver cancer. Nat Genet 2016;48:500-9.
31. Lee HJ, Kim SK, Cho D, Lee JJ. Cellular immunotherapy as a beacon of hope for hematological malignancies. Blood Res 2015;50:126-8.
32. Schmidt N, Neumann-Haefelin C, Thimme R. Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy.
Dig Dis 2012;30:483-91.
33. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed
with tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009;49:124-32.
34. El Ansary M, Mogawer S, Elhamid SA, Alwakil S, Aboelkasem F, et al. Immunotherapy by autologous dendritic cell vaccine in
patients with advanced HCC. J Cancer Res Clin Oncol 2013;139:39-48.
35. Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Mukaida N, et al. Enhancement of tumor-specific T-cell responses by transcatheter
arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int J cancer 2010;126:2164-74.
36. Pexa-Vec/Nexavar combination fails phase III trial in liver cancer. Available from: https://www.genengnews.com/news/pexa-vec-
nexavar-combination-fails-phase-iii-trial-in-liver-cancer/. [Last accessed on 9 Oct 2019]
37. Liu D, Staveley-O’Carroll KF, Li G. Immune-based therapy clinical trials in hepatocellular carcinoma. J Clin Cell Immunol
2015;6:376.
38. Onishi S, Saibara T, Fujikawa M, Sakaeda H, Matsuura Y, et al. Adoptive immunotherapy with lymphokine-activated killer cells plus
recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma. Hepatology 1989;10:349-53.
39. Kawata A, Une Y, Hosokawa M, Wakizaka Y, Namieno T, et al. Adjuvant chemoimmunotherapy for hepatocellular carcinoma
patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol 1995;18:257-62.
40. Wang Y, Chen H, Wu M, Bao J, Cong W, et al. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-
infiltrating lymphocytes. Chin Med J (Engl) 1997;110:114-7.
41. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of
hepatocellular carcinoma: a randomised trial. Lancet 2000;356:802-7.
42. Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for
hepatocellular carcinoma. Gastroenterology 2015;148:1383-91.e6.
43. Maus M V, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood
2014;123:2625-35.
44. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, et al. Immunotherapy of HCC metastases with autologous T cell receptor
redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.
45. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-
small-cell lung cancer. N Engl J Med 2016;375:1823-33.
46. Robert C, Long GV, Brady B, Dutriaux C, Maio M, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N
Engl J Med 2015;372:320-30.
47. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab
in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.